Atrium Therapeutics RNA Insider Ownership

NASDAQ RNA
$8.32 +0.27 (+3.35%)
At close: Oct 27, 2026 · 4:00 PM EDT

Insider Holdings by Owner

491.73K Shares

Insider Ownership Statistics

as of 30 Sep, 2026
Insider Ownership
2.87%
▲+0.637% pp QoQ
Shares Held by Insiders
491.73K
filed for Sep 2026
▲+28.45% QoQ
Shares Outstanding
17.11Mn
17,106,000 shares
Direct Holdings
491.73K
Indirect: 0
Net Open-Market Trades
0
no open-market trades in Sep 2026
Insiders Holding Shares
8
with Form 4 holdings on file

Shares Owned by Insiders

Shares held % of outstanding
Latest —
Average ownership —
Peak ownership —

Open-Market Insider Trades

Bought Sold
Latest quarter —
Net over range —
Net-buying quarters —

Insider Ownership Summary

Over the past year, RNA insiders did not buy or sell the stock on the open market.

Form 4 Holdings

Insiders Holding RNA

Insiders 8
Shares held 491.73K
Of outstanding 2.87%
# Insider Position Direct Indirect Total Share of Insiders Last Filed
1 Sarah Boyce Director 138,668 0 138,668 28.2% 22 Sep, 2026
2 Kathleen P. Gallagher Director, Officer 119,729 0 119,729 24.3% 22 Sep, 2026
3 Steven George Hughes Chief Medical Officer 51,638 0 51,638 10.5% 22 Sep, 2026
4 Husam Younis Chief Scientific Officer 41,441 0 41,441 8.4% 22 Sep, 2026
5 Rocio Martin Hoyos Chief Strategy Officer 38,340 0 38,340 7.8% 22 Sep, 2026
6 Brendan R. Winslow Chief Financial Officer 36,859 0 36,859 7.5% 22 Sep, 2026
7 Stephanie Kenney Officer 33,085 0 33,085 6.7% 22 Sep, 2026
8 W. Michael Flanagan Director 31,974 0 31,974 6.5% 22 Sep, 2026

Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.

Form 4 Filings

25 Insider Transactions

Source SEC Form 4
Latest quarter Sep 2026
Download Data
Date Insider Position Transaction Shares Price Value Shares Held After Ownership
18 Sep, 2026 Steven George Hughes Chief Medical Officer Disposed F 21,459 $8.95 $192.06K 51,638 Direct
18 Sep, 2026 Kathleen P. Gallagher Director, Officer Disposed F 11,632 $8.95 $104.11K 119,729 Direct
18 Sep, 2026 Brendan R. Winslow Chief Financial Officer Disposed F 6,742 $8.95 $60.34K 36,859 Direct
18 Sep, 2026 W. Michael Flanagan Director Disposed F 22,812 $8.95 $204.17K 31,974 Direct
18 Sep, 2026 Sarah Boyce Director Disposed F 126,418 $8.95 $1.13Mn 138,668 Direct
18 Sep, 2026 Stephanie Kenney Officer Disposed F 2,375 $8.95 $21.26K 33,085 Direct
18 Sep, 2026 Rocio Martin Hoyos Chief Strategy Officer Disposed F 8,320 $8.95 $74.46K 38,340 Direct
18 Sep, 2026 Husam Younis Chief Scientific Officer Disposed F 11,216 $8.95 $100.38K 41,441 Direct
20 Apr, 2026 Husam Younis Chief Scientific Officer Acquired A 30,000 $0.00 $0 52,657 Direct
20 Apr, 2026 Rocio Martin Hoyos Chief Strategy Officer Acquired A 30,000 $0.00 $0 46,660 Direct
20 Apr, 2026 Stephanie Kenney Officer Acquired A 30,000 $0.00 $0 35,460 Direct
20 Apr, 2026 Steven George Hughes Chief Medical Officer Acquired A 30,000 $0.00 $0 73,097 Direct
20 Apr, 2026 Kathleen P. Gallagher Director, Officer Acquired A 102,500 $0.00 $0 131,361 Direct
20 Apr, 2026 Brendan R. Winslow Chief Financial Officer Acquired A 30,000 $0.00 $0 43,601 Direct
20 Apr, 2026 Rocio Martin Hoyos Chief Strategy Officer Acquired A 60,000 $0.00 $0 60,000 Direct
20 Apr, 2026 Steven George Hughes Chief Medical Officer Acquired A 60,000 $0.00 $0 60,000 Direct
20 Apr, 2026 Kathleen P. Gallagher Director, Officer Acquired A 205,000 $0.00 $0 205,000 Direct
20 Apr, 2026 Husam Younis Chief Scientific Officer Acquired A 60,000 $0.00 $0 60,000 Direct
20 Apr, 2026 Brendan R. Winslow Chief Financial Officer Acquired A 60,000 $0.00 $0 60,000 Direct
20 Apr, 2026 Stephanie Kenney Officer Acquired A 60,000 $0.00 $0 60,000 Direct